| 1.4699 0.02 (1.37%) | 10-07 14:46 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.52  |
1-year : | 3.09 |
| Resists | First : | 2.16 |
Second : | 2.65 |
| Pivot price | 1.72 |
|||
| Supports | First : | 1.37 |
Second : | 1.13 |
| MAs | MA(5) : | 1.44 |
MA(20) : | 1.75 |
| MA(100) : | 1.83 |
MA(250) : | 3.39 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 5.3 |
D(3) : | 2.8 |
| RSI | RSI(14): 38.2 |
|||
| 52-week | High : | 11.39 | Low : | 1.3 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ATNF ] has closed above bottom band by 21.6%. Bollinger Bands are 27% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.47 - 1.48 | 1.48 - 1.49 |
| Low: | 1.38 - 1.4 | 1.4 - 1.41 |
| Close: | 1.4 - 1.42 | 1.42 - 1.44 |
1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
Thu, 03 Oct 2024
180 Life Sciences Corp. - Corporate Updates - AccessWire
Wed, 18 Sep 2024
ATNF Stock Earnings: 180 Life Sciences Reported Results for Q2 2024 - MSN
Thu, 12 Sep 2024
180 Life Sciences Announces CFO Resignation and New Board Appointments - TipRanks
Tue, 02 Jul 2024
180 Life Sciences gets extension to stay on Nasdaq - Investing.com
Wed, 06 Mar 2024
symbol__ Stock Quote Price and Forecast - CNN
Mon, 31 Jul 2023
180 Life Sciences Files A Provisional Patent For CBD-Based Appetite Suppressant - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 1 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 1.4 (%) |
| Held by Institutions | 6.3 (%) |
| Shares Short | 61 (K) |
| Shares Short P.Month | 32 (K) |
| EPS | -11.2 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.44 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -63.5 % |
| Return on Equity (ttm) | -398.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -8.58 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -4 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -0.14 |
| PEG Ratio | 0 |
| Price to Book value | -3.35 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.36 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|